MA26701A1 - PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSTIONS PHARMACEUTIQUES LES CONTENANT. - Google Patents

PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSTIONS PHARMACEUTIQUES LES CONTENANT.

Info

Publication number
MA26701A1
MA26701A1 MA25821A MA25821A MA26701A1 MA 26701 A1 MA26701 A1 MA 26701A1 MA 25821 A MA25821 A MA 25821A MA 25821 A MA25821 A MA 25821A MA 26701 A1 MA26701 A1 MA 26701A1
Authority
MA
Morocco
Prior art keywords
preparation
pyrazolopyrimidinones
pharmaceutical compositions
inhibitors
gmpc
Prior art date
Application number
MA25821A
Other languages
English (en)
Inventor
Edward Bunnage Mark
Nigel Maw Graham
Wood Anthony
Paul Mathias John
James Rawson David
Derek Albert Street Stephen
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA26701A1 publication Critical patent/MA26701A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

DEPOSANT Société dite : PFIZER INC, REVENDICATION DE PRIORITES GB 23/10/1998 9823102.0 Voir en annexe le titre de l'invention et le texte de l'abrégé Pyrazolopyrimidinones nouvelles inhibitrices de PDE-5 GMPc, procédé pour leur préparation et compositions pharmaceutiques les contenant L'invention concerne des composés de formule IA ou IB dans laquelle R1, R2, R3, R4 et A représentent divers radicaux. Elle concerne également un procédé pour leur préparation et des formulations pharmaceutiques les contenant. Application : utilisation de ces composés et formulations pharmaceutiques, inhibant la PDE-5 GMPc, pour le traitement ou la prévention de diverses maladies.
MA25821A 1998-10-23 1999-10-20 PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSTIONS PHARMACEUTIQUES LES CONTENANT. MA26701A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9823102.0A GB9823102D0 (en) 1998-10-23 1998-10-23 Pharmaceutically active compounds

Publications (1)

Publication Number Publication Date
MA26701A1 true MA26701A1 (fr) 2004-12-20

Family

ID=10841068

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25821A MA26701A1 (fr) 1998-10-23 1999-10-20 PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSTIONS PHARMACEUTIQUES LES CONTENANT.

Country Status (7)

Country Link
US (1) US6333330B1 (fr)
GB (1) GB9823102D0 (fr)
GT (1) GT199900183A (fr)
MA (1) MA26701A1 (fr)
PE (1) PE20001114A1 (fr)
TN (1) TNSN99198A1 (fr)
UY (1) UY25795A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6627632B2 (en) * 1998-12-14 2003-09-30 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
DK1474143T3 (da) 2002-01-25 2009-01-26 Modular Properties Ltd Fremgangsmåder og sammensætninger til bahandling af mandlig erektil dysfunktion
US20090035221A1 (en) * 2002-01-25 2009-02-05 Ramsey Sallis Methods and Compositions for Treatment of Erectile Dysfunction
US20090257956A1 (en) * 2002-01-25 2009-10-15 Ramsey Sallis Treatment Method for Treatment of Erectile Dysfunction and Premature Ejaculation
US20050048573A1 (en) * 2003-02-03 2005-03-03 Plexxikon, Inc. PDE5A crystal structure and uses
US20050079548A1 (en) * 2003-07-07 2005-04-14 Plexxikon, Inc. Ligand development using PDE4B crystal structures
GB0327319D0 (en) * 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
EP1708718A1 (fr) 2004-01-22 2006-10-11 Pfizer Limited Derives de triazole inhibant l'activite antagoniste de vasopressine
EP1847531A4 (fr) * 2005-02-09 2009-04-22 Takeda Pharmaceutical Derive de pyrazole
BRPI0621588A2 (pt) * 2006-04-04 2011-12-13 Dong A Pharm Co Ltd agente para prevenção e tratamento da hiperplasia prostática compreendendo o composto pirazolpirimidinona
AR109596A1 (es) 2016-09-09 2018-12-26 Incyte Corp Compuestos pirazolopiridina y sus usos
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US20180072741A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
WO2018152220A1 (fr) 2017-02-15 2018-08-23 Incyte Corporation Composés de pyrazolopyridine et leurs utilisations
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
DK3755703T3 (da) 2018-02-20 2022-06-27 Incyte Corp N-(phenyl)-2-(phenyl)pyrimidin-4-carboxamidderivater og relaterede forbindelser som hpk1-inhibitorer til behandling af kræft
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
WO2020068729A1 (fr) 2018-09-25 2020-04-02 Incyte Corporation Composés pyrazolo[4,3-d]pyrimidine en tant que modulateurs des alk2 et/ou fgfr
KR20220059480A (ko) 2019-08-06 2022-05-10 인사이트 코포레이션 고체 형태의 hpk1 억제제

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4371843A (en) 1980-07-07 1983-02-01 Bell Telephone Laboratories, Incorporated Semiconductor differential amplifier circuit with feedback bias control
US4670978A (en) 1985-01-28 1987-06-09 Amp Incorporated Connector mounting press
US4663326A (en) 1985-04-04 1987-05-05 Warner-Lambert Company Pyrazolo[4,3-d]pyrimidine-5,7-(4H,6H)dione or -5-thione-7-one analogs
US4666908A (en) 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
US5075310A (en) 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators
GB8817651D0 (en) 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9119704D0 (en) 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic agents
GB9121028D0 (en) 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
GB9202238D0 (en) 1992-02-03 1992-03-18 Wellcome Found Compounds
US5294612A (en) 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
US5734053A (en) 1992-06-26 1998-03-31 Pfizer Inc Purinone antianginal agents
GB9213623D0 (en) 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents
GB9218322D0 (en) 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9315017D0 (en) 1993-07-20 1993-09-01 Glaxo Lab Sa Chemical compounds
GB9423911D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9423910D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
JPH11501926A (ja) * 1995-03-10 1999-02-16 サノフィ ファーマシューティカルズ インコーポレイティド ６−アリールピラゾロ［３，４−ｄ］ピリミジン−４−オン、並びにその組成物及び使用法
US5656629A (en) 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
GB9612514D0 (en) 1996-06-14 1996-08-14 Pfizer Ltd Novel process
CA2288910C (fr) 1997-04-25 2003-06-24 Pfizer Inc. Pyrazolopyrimidinones pour des dysfonctions sexuelles
ES2203078T3 (es) 1998-04-20 2004-04-01 Pfizer Inc. Parazolopirimidinonas inhibidoras de gmpc pde5 para el tratamiento de la disfuncion sexual.
US6087368A (en) 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase
GB9823101D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds

Also Published As

Publication number Publication date
UY25795A1 (es) 2000-08-21
US6333330B1 (en) 2001-12-25
GT199900183A (es) 2001-04-14
PE20001114A1 (es) 2000-10-28
TNSN99198A1 (fr) 2005-11-10
GB9823102D0 (en) 1998-12-16

Similar Documents

Publication Publication Date Title
MA26689A1 (fr) Derives de tetrahydroquinoleine substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26688A1 (fr) 4-carboxamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA24729A1 (fr) Macrolides nouveaux.
MA26700A1 (fr) FORMULATIONS PHARMACEUTIQUES D'INHIBITEURS DE PDE-5 DE GMPc à LIBERATION CONTROLEE, ET PROCEDE POUR LEUR PREPARATION.
MA27439A1 (fr) Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase
MA26697A1 (fr) Composes nouveaux inhibiteurs de gsk-3 et compositions pharmaceutiques les contenant
MA26723A1 (fr) Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA28747B1 (fr) Dérivés de pyridine
MA26718A1 (fr) Derives de quinoleine-2-one a substituant heteroaryle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA24694A1 (fr) Derives de thienopyrimidine et thienopyridine utiles comme agents anticancereux, et compositions les contenant.
TNSN97198A1 (fr) Derives de 6-phenylpyridyl-2- amine et compositions pharmaceutiques les contenant
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
TNSN99155A1 (fr) 1-aryl-3-arylmethyl-1,8-naphtyridine-4(1h)-ones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA27676A1 (fr) 2-amino-6-(2-substitue-4-phenoxy)-substitue-pyridines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA25035A1 (fr) Derives de 3-azabicyclo [3,1,0] hexane nouveaux, procede pour leur preparation et compositions les contenant
MA26717A1 (fr) Macrolides nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98084A1 (fr) Derives de macrolides substitues en position c-4
ATE361287T1 (de) Neue indol-2-on derivate
MA26720A1 (fr) Composes nouveaux inhibiteurs de reabsorption de monoamines, procede pour leur preparation, et compositions pharmaceutiques les contenant.
TNSN97145A1 (fr) Derives 6,5-heterobicycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26733A1 (fr) Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26727A1 (fr) Derives nouveaux de pyrimidine inhibiteurs de sorbitol deshydrogenase, leur procede de preparation et compositions pharmaceutiques les contenant
TNSN99073A1 (fr) Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99198A1 (fr) PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
MA29213B1 (fr) Quinolones a substitution macrolones - amino